Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18494814 | 0.86 | RXRA (0.32) | RXRAGRIN1GRIN2B | |
| SCHEMBL25897329 | 0.81 | APLNR (0.34) | APLNR | |
| SCHEMBL12120619 | 0.77 | RXRA (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL21516067 | 0.76 | RXRA (0.31) | RXRAGRIN1GRIN2B | |
| SCHEMBL22725520 | 0.75 | RXRA (0.30) | RXRAGRIN1GRIN2B | |
| SCHEMBL19919582 | 0.74 | APLNR (0.36) | APLNR | |
| SCHEMBL20341255 | 0.72 | RXRA (0.30) | RXRAGRIN1GRIN2B | |
| SCHEMBL10267302 | 0.71 | RXRA (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL26532695 | 0.71 | CYP3A4 (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL22725522 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-10005783-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180127427-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2018-05-10 | — | — | US | disclosed |
| US-9676783-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127427-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | APLNR 2883/4885RXRA 1741/4885GRIN1 2375/4885 |
| US-10005783-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | TYMP, TYMS, P2RX7 | APLNR 2883/4885RXRA 1741/4885GRIN1 2375/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | APLNR 2971/4885RXRA 1404/4885GRIN1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.